DUXAP8 and cancer: As illustrated in Figure 1A, there was a pooled HR = 1.63 between DUXAP8 and the OS (95% CI, 1.49–1.77, p < 0.001), revealing significantly worse OS in the cancer patients with high expression of DUXAP8.